Evidence map›Paper›PMID 41501299›Full record

ArticleBreast cancer research and treatment2026

Outcomes of patients with de novo oligometastatic breast cancer treated with curative intent at a single institution.

Emily L Chen, Hillary Heiling, Tianyu Li, Jennifer R Bellon, Faina Nakhlis, Heather A Parsons, Alyssa Martin, Harold J Burstein, Sara M Tolaney, Craig Snow and 4 more

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Breast cancer research and treatment, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07586319 (Effectiveness of Primary Tumour Surgery in Oligometastatic Breast Cancer for Improving Overall Survival), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07586319 naenrolling by invitationnot on this map

Effectiveness of Primary Tumour Surgery in Oligometastatic Breast Cancer for Improving Overall Survival: A Quasi-Experimental Study

TypeinterventionalSponsorSharif Medical Research CenterRan2026 to 2031Enrolled110ConditionsSurvival OutcomesArmssurgery in accordance with current clinical guidelines, modified radical mastectomy or breast conservation surgery
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Emily L ChenDepartment of Medicine, Brigham and Women's Hospital, Boston, MA, USA.
Hillary HeilingDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Tianyu LiDepartment of Data Science, Dana-Farber Cancer Institute, Boston, MA, USA.
Jennifer R BellonHarvard Medical School, Boston, MA, USA.
Faina NakhlisHarvard Medical School, Boston, MA, USA.
Heather A ParsonsHarvard Medical School, Boston, MA, USA.
Alyssa MartinBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Harold J BursteinHarvard Medical School, Boston, MA, USA.
Sara M TolaneyHarvard Medical School, Boston, MA, USA.
Craig SnowBreast Oncology Program, Dana-Farber Brigham Cancer Center, Boston, MA, USA.
Nabihah TayobHarvard Medical School, Boston, MA, USA.
Lior Z BraunsteinDepartment of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Nancy U LinHarvard Medical School, Boston, MA, USA.
Sarah SammonsHarvard Medical School, Boston, MA, USA. Sarahl_sammons@dfci.harvard.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeDe novo oligometastatic breast cancer (OMBC) is often defined as up to five metastases in two or fewer organs at presentation. Studies have suggested favorable outcomes for patients with OMBC; however, management remains controversial. We analyzed outcomes of patients with de novo OMBC treated with physician-expressed curative intent at a single institution.

methodsWe identified patients by performing a keyword search for terms of interest within institutional electronic medical records. We defined OMBC as four or fewer metastases in one organ. Primary surgery was required for inclusion in the analytic cohort. Recurrence-free survival (RFS) and overall survival (OS) were evaluated using Kaplan-Meier methods.

resultsThirty-nine patients were identified: 12 hormone receptor-positive (HR+)/HER2+ , 2 HR-negative (HR-)/HER2-, 21 HR+ /HER2-, and 4 HR-/HER2+ . Thirty-three patients (84.6%) had 1 metastasis at diagnosis. Median age was 47 years (28-69). Twenty-nine patients (74.4%) underwent adjuvant radiation to the breast. Two-thirds of patients underwent metastasis-directed therapy. Five-year OS was 77% (95% CI 61-95%). Median RFS was 7.1 years (95% CI 4.62-not reached). Five-year RFS was 58% (95% CI 42-81%).

conclusionsSurvival outcomes were favorable among this select cohort. Optimal treatment for de novo OMBC remains unclear. Curative intent trials are underway for HER2+ de novo OMBC.

Indexed as

Breast NeoplasmsAdultAgedCombined Modality TherapyErb-b2 Receptor Tyrosine KinasesFemaleHumansKaplan-Meier EstimateMiddle AgedNeoplasm MetastasisPrognosisTreatment OutcomeERBB2 protein, humanErb-b2 Receptor Tyrosine KinasesBreast cancerCurative intentMetastaticOligometastasticSurvival

Identifiers

PMID41501299

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.